COVID-19 vaccine by AZ, along with CMA, recommended that those over 65 years of age should review it by the Vaccination Specialist Committee, the Central Pharmaceutical Affairs Review Committee of the MFDS said it was because on-site judgment was important.

In a briefing held on the 5th, Chairman Il-Hwan Oh said, "Because the data on the elderly are relatively limited, the MFDS has made a decision to carefully judge the benefits of vaccination and the risks that may occur if not."

He said, "The clinical trial results so far are not statistically verifiable because the number of cases has been small. But it doesn't mean that this doesn't work or put a decision on hold"

On